SHARE THIS POST

17 January 2018

Commercialisation agreement with UK-based Precision Healthcare to launch cannaQIX®10 and 50 in the UK UK launch is planned for Q1 2018

Highlights:

  • Commercialisation agreement to market and distribute Creso’s hempbased human health nutraceuticals – cannaQIX®10 and 50 – in the UK.
  • The UK launch is planned for Q1 2018.
  • Also follows cannaQIX® being confirmed as a Food Supplement in the UK.
  • Swiss regulatory authorities have issued a free sales certificate for the export of the product into the UK from Switzerland.
  • cannaQIX® is a unique standardised nutraceutical product, in a proprietary delivery formulation, that contains organic hemp extract with CBD, vitamins and zinc.
  • cannaQIX® aims to reduce stress and to support mental and nervous functions in humans.

Creso Pharma Limited (ASX:CPH, the “Company” or “Creso”) is pleased to announce it has secured a commercialisation agreement with UK-based Precision Healthcare Ltd to market and distribute Creso Pharma’s cannaQIX®10 and 50 hemp-based human health nutraceutical products in the UK.

The UK launch of cannaQIX®10 and 50 is planned for Q1 2018.

Precision Healthcare Ltd is a privately held healthcare company which specialises in the development of consumer healthcare products. It is part of Precision Marketing Group, a leading service provider to international pharmaceutical and healthcare companies. The company sells and distributes consumer healthcare brands to mass retailers and independent pharmacies covering more than 5000 points of sale in the UK.

The agreement covers the non-exclusive marketing and distribution of cannaQIX®10 and 50 in the UK market, targeting pharmacies and health food stores.

cannaQIX® is a unique standardised nutraceutical product, in a proprietary formulation, that contains full plant organic hemp extract with CBD, vitamins and zinc, aiming to reduce stress and to support mental and nervous functions in humans.

The commercialisation agreement follows Creso receiving confirmation for cannaQIX® as a Food Supplement from the UK Trading Standard Office (TSO), Hertfordshire County Council, as the primary regulatory authority.

Swiss regulatory authorities have issued a certificate of free sales for the export of the product into the UK from Switzerland.

“We are delighted to partner with Precision Healthcare and to have obtained the necessary regulatory approvals for cannaQIX® in the UK – both significant milestones for our company,” said Creso Pharma Chief Executive Officer and Co-Founder, Dr. Miri Halperin Wernli.

Precision Marketing Group Chief Executive Officer Matthew Caldwell-Nichols added: “We are very pleased to work with Creso Pharma who are a leading Swiss-based cannabis and hemp healthcare company to market their innovative cannabis and hemp-based products, and we are looking forward to a successful business partnership.”

About cannaQIX®

The cannaQIX® range of products are hemp-based nutraceuticals using Creso’s proprietary innovative delivery technology. They contain organic hemp extract with CBD, vitamins and zinc, aiming to reduce stress and to support mental and nervous functions.

The proprietary QIX-technology based delivery system contains capsicum, which accelerates the blood circulation in the mouth enhancing the buccal, sublingual delivery of the CBD, vitamins and zinc into the bloodstream.

The product is safe, well tolerated, non-euphoric and non-addictive and sugar free. The standardised, user-friendly strength and formulation allows precise dosage control, ensuring a reliable and stable effect over several days.

The cannaQIX® range has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Creso’s partner Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality with a “Swiss Made” label.

With cannaQIX®, Creso Pharma offers consumers a safe and effective certified Food Supplement with CBD, with broad market reach and without the need for medical prescriptions.

Investor Enquiries:

Gabriella Hold Media + Capital Partners M: 04111 364 382 E: gabriella.hold@mcpartners.com.au

Corporate Queries:

EverBlu Capital Level 39 Aurora Place 88 Phillip Street, Sydney NSW 2000 E: info@everblucapitalcom P: +61 2 8249 0000

About Creso Pharma

Creso Pharma brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis- and hemp-derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. Creso Pharma Switzerland develops, produces and markets worldwide cannabis and hemp- derived therapeutics, nutraceuticals and life cycle products for humans and complementary feed products for animals.

About Precision Healthcare Ltd

Precision Healthcare Ltd is a UK company specialized in market development of consumer healthcare products. The company was founded in 2014 and is part of Precision Marketing Group Ltd., a leading service provider to international pharmaceutical and healthcare companies. Precision Healthcare Ltd is a privately held healthcare company. The company sells and distributes consumer healthcare brands to mass retailer as well as to independent pharmacies. Precision Healthcare covers over 5000 point of sales in UK and has a full consumer ecommerce platform.

About Domaco, Dr. med Aufdermaur AG

Domaco, Dr. med Aufdermaur AG is a Swiss-based food and pharma development company that owns the rights to a number of innovative delivery systems used to administer active ingredients through galenic forms which is a way of preparing and compounding medicines in order to optimize their absorption.